A new prospective study evaluating advanced diagnostics for unclear cystic fibrosis cases may shape regulatory pathways for CFTR testing devices and related procedures. Not yet recruiting status indicates planning across multiple centers including Royal Brompton and Harefield NHS Foundation Trust, King’s College London, UMC Utrecht, and Imperial College London. The description specifies rectal biopsy as an endoscopy based procedure and a blood test for CFTR genotyping as key interventions in the context of CF and CFTR related disorders. The study’s public record was posted on 2026 February 15 and provides a ClinicalTrials.gov reference link. The description indicates a regulatory oriented evaluation of how these diagnostics might be used to clarify uncertain CF diagnoses while considering safety, performance and intended purpose for devices and tests. The overall status is not yet recruiting.
What changed in CF diagnostic landscape?
The description details an approach that combines histologic and genetic testing to address unclear CF diagnoses. The use of rectal biopsy alongside CFTR genotyping reflects expanding diagnostic inputs that may influence how clinicians establish CF and CFTR related disorders. This study highlights a regulatory perspective on how such diagnostics could be integrated into clinical pathways while adhering to safety and performance expectations for devices and tests.
Who is affected by this prospective study?
The study targets people with an unclear diagnosis of cystic fibrosis. This population includes individuals for whom standard tests have not produced a definitive result. Understanding how these advanced diagnostics perform in this group could inform future regulatory decisions and clinical practice.
What diagnostic approaches are studied?
The trial lists rectal biopsy taken opportunistically during endoscopy performed for other reasons as one procedure. In addition, a blood test for CFTR genotyping is included as a genetic assessment. Together these modalities reflect an integrated strategy to clarify CF and CFTR related disorders in complex cases. All statements relate to the trial description and standard clinical procedures.
What are regulatory considerations for these diagnostics?
From a regulatory perspective the trial touches on how devices and tests used for CFTR genotyping and for biopsy based assessments may require compliance with regulatory standards. MDR style language applies to intended purpose, performance and safety. Manufacturer statements would be labeled as such and any claims require clear evidence. The discussion remains descriptive and focused on the implications for regulatory pathways rather than asserting outcomes.
Who sponsors and what is the trial status?
The listed sponsors are Royal Brompton and Harefield NHS Foundation Trust, King’s College London, UMC Utrecht and Imperial College London. The study status is not yet recruiting, indicating planning or early development phase and no enrollment at this time.
- 1. What is the focus of the study?
- 2. What procedures are involved?
- 3. When can results be expected or what is the current status?
In summary, the prospective study places advanced diagnostics at the center of efforts to clarify unclear CF diagnoses. The combination of rectal biopsy and CFTR genotyping signals a potential shift in how diagnostic pathways are defined and regulated, with attention to safety and performance standards. Stakeholders should monitor updates from the sponsor institutions and from ClinicalTrials.gov for milestones and results.
This article is intended for clinical and regulatory professionals. It does not provide legal advice. Cite MDR guidance and national regulations for device and test approvals and clinical use.
https://clinicaltrials.gov/study/NCT07402434?term=medical+device
Publication date context: 2026-02-15